ImmuneSpec
ActiveSummary
ImmuneSpec has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.64M and a net result of €-202k. Equity is growing by ~15.4% per year across the filed fiscal years. Its solvency ranks better than 69% of 213 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.9% (low).
Checked score
Score 2025
72
/ 100
Healthy
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability62▼-4
Solvency100▲+1
Growth78=
Track record94
Bankruptcy probability, 12 months
0.9%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €180k at 30 days acceptable
Liquidity ample (current ratio 3.23 against 3.67 in 2024; short-term debt: 12.6% and cash: 5.4% of total assets), and 25.4% of the assets are financed with debt.
Credit check for your own amount and term
Signals
Four signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Sector 72
lower
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
74.6%
Return on assets
-5.7%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 08-06-2026, 53 days ahead of the deadline.
NBB · 3 filingsDeviation from the deadline
2025
53 d early
2024
64 d early
2023
50 d early
← before the deadline
after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
24-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€2.64M▲ 12.7%
2024 · €2.34M
2023: €1.92M
2024: €2.34M
2023 → 2025
Total assets
€3.54M▲ 11.2%
2024 · €3.18M
2023: €3.21M
2024: €3.18M
2023 → 2025
Net result
€-202k▼ 159%
2024 · €-78k
2023: €-397k
2024: €-78k
2023 → 2025
Working capital
€991k▲ 21.1%
2024 · €818k
2023: €660k
2024: €818k
2023 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line202320242025Trend
Equity€1.92M-€2.34M▲ 22.0%€2.64M▲ 12.7%
Operating result€-373k-€-46k▲ 87.6%€-178k▼ 283%
Net result€-397k-€-78k▲ 80.4%€-202k▼ 159%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €178k in 2025 against €46k in 2024; the loss grows.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €3.54M
Fixed assets
€2.10M ▲ 2.2%
Current assets
€1.44M ▲ 27.6%
Equity and liabilities €3.54M
Equity
€2.64M ▲ 12.7%
Debt
€897k ▲ 6.9%
Debt's share of the balance-sheet total falls from 26.4% to 25.4%. Equity and debt are higher.
Key figures and ratios
EBITDA
€506k▲
2024 · €490k
Cash flow
€482k▲
2024 · €459k
Current ratio
3.23▼
2024 · 3.67
Debt to equity
0.34▼
2024 · 0.36
ROE
-7.6%▼
2024 · -3.3%
ROA
-5.7%▼
2024 · -2.5%
Interest coverage
13.01▲
2024 · 11.58
Debt ≤ 1 year
€444k▲
2024 · €306k
Debt > 1 year
€385k▼
2024 · €453k
Income taxes
€-12k▼
2024 · €-11k
Staff costs
€376k▲
2024 · €207k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 52 lines
Balance sheet
Code20242025
Assets
Total assets20/58€3.18M€3.54M▲
Formation expenses20€0-
Fixed assets21/28€2.05M€2.10M▲
Intangible fixed assets21€1.05M€1.10M▲
Tangible fixed assets22/27€981k€975k▼
Plant, machinery and equipment23€98k€101k▲
Furniture and vehicles24€23k€33k▲
Leasing and similar rights25€858k€839k▼
Other tangible fixed assets26€2k€1k▼
Assets under construction and advance payments27€0-
Financial fixed assets28€19k€26k▲
Current assets29/58€1.12M€1.44M▲
Amounts receivable within one year40/41€960k€689k▼
Trade receivables40€816k€474k▼
Other amounts receivable41€145k€215k▲
Current investments50/53-€450k
Cash at bank and in hand54/58€113k€192k▲
Deferred charges and accrued income490/1€51k€104k▲
Equity and liabilities
Total equity and liabilities10/49€3.18M€3.54M▲
Equity10/15€2.34M€2.64M▲
Contributions10/11€2.82M€3.32M▲
Profit (loss) carried forward14€-475k€-677k▼
Amounts payable17/49€839k€897k▲
Amounts payable after more than one year17€453k€385k▼
Financial debts170/4€453k€385k▼
Amounts payable within one year42/48€306k€444k▲
Current portion of amounts payable after more than one year42€166k€236k▲
Trade debts44€107k€143k▲
Suppliers440/4€107k€143k▲
Advances received on contracts in progress46€0-
Taxes, remuneration and social security45€33k€65k▲
Taxes450/3€4k€9k▲
Remuneration and social security454/9€29k€56k▲
Other amounts payable47/48€28€34▲
Accrued charges and deferred income492/3€79k€68k▼
Income statement
Code20242025
Remuneration, social security and pensions62€207k€376k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€536k€684k▲
Other operating charges640/8€118€2k▲
Non-recurring operating charges66A€66€0▼
Gross operating margin9900€697k€884k▲
Operating profit (loss)9901€-46k€-178k▼
Financial income75/76B€201€3k▲
Recurring financial income75€201€3k▲
Financial charges65/66B€42k€39k▼
Recurring financial charges65€42k€39k▼
Profit (loss) for the period before taxes9903€-89k€-214k▼
Income taxes67/77€-11k€-12k▼
Profit (loss) for the period9904€-78k€-202k▼
Profit (loss) for the period to be appropriated9905€-78k€-202k▼
Appropriation of the result
Profit (loss) to be appropriated9906€-475k€-677k▼
Profit (loss) brought forward from the previous period14P€-397k€-475k▼
Social balance
Average headcount (FTE)90873.45.7▲
The notes to these accounts (22 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
08-06
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
28-05
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Equity above €2MEq €2.34M ▲22%
Equity rises from €1.92M to €2.34M.
11-06
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
9 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Niel · 1 establishment unit since 2023
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Galileilaan 182845 NielGround area
896 m²
Building footprint
921 m²
Volume, LiDAR
14,379 m³
Parcel 11030C0269/00C000, Flanders · tallest building 18.8 m, ±5 floors. Linked by address, not a title deed.
1 establishment unit
ImmuneSpec
since 20232.341.387.879
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11030C0269/00C000 | Flanders | 896 m² | 1 · 921 m² | 18.8 m · 5 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Public money · subsidies and aid
Flemish government
2023 to 2025 · 12 entries · 540,996 EUR awarded · 420,323 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 5 | 1,662 EUR | 1,662 EUR |
| 2024 | 3 | 450 EUR | 218,747 EUR |
| 2023 | 4 | 538,884 EUR | 199,914 EUR |
Schemes
Ontwikkelingsproject
Kmo-groeisubsidie: steun voor groeitrajecten bij kmo's (stopgezet)
Subsidies voor internationaal ondernemen
Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)
Similar companies · same sector, comparable size
WEL Research Institute
BE 0812.367.476
Wavre · Eq €2.66M
Dr. Lieven WOSTYN
BE 0467.516.640
Koksijde · Eq €2.70M
ERC BELGIUM
BE 0895.963.165
Gembloux · Eq €2.54M
White Raven
BE 0782.537.107
Liège · Eq €2.53M
SYNGULON
BE 0521.816.349
Seraing · Eq €2.52M
Of 761 companies in sector 72101 we hold annual accounts for 481. 244 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded27-01-2023
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
Sources
Crossroads Bank for EnterprisesNational Bank · 3 filingsAddress and cadastre registers
Scores and ratios are computed by Checked and are not a credit decision.